Stemfect RNA Transfection Kit

00-0069

Brand: Stemgent™

Purchase product: USA Store

Product Code Pack Size Price in
The Americas
Price in EMEA
00-0069 1 kit USD $ 270.00 GBP £ 209.03 EUR € 237.25

Prices do not include shipping and handling charges.

stemfect-rna-transfection-kit-p196-82_medium

The StemAb RNA Transfection Kit is a proprietary mixture of lipid components is specifically designed for in vitro RNA transfection. This kit has been shown to deliver mRNA, siRNA and miRNA. StemAb RNA Transfection Kit provides greater than or equal to 90% transfection efficiency of mRNA into a range of cell types with greater than 95% viability; these cell types include human embryonic stem (hES) cells, Jurkat cells, human fibroblasts, and HEK293T-cells. StemAb RNA Transfection Kit has been successfully used to deliver RNA to human ES cells, dendritic cells, and retinal pigment epithelial cells. There is no need to serum-starve cells using this kit as the transfection efficiency remains greater than or equal to 90% in the presence of serum.

153683960800-0069_figure1
Higher levels of protein expression with StemFect RNA Transfection Kit. BJ fibroblasts were transfected with GFP mRNA. GFP expression was assessed at 18 h post-transfection.

153683978000-0069_figure2

Titrate protein expression by modifying the amount mRNA used for transfection. BJ fibroblasts were transfected with eGFP mRNA. Transfection efficiency and GFP intensity were determined at 18 h post-transfection.

153683983600-0069_figure3a

High efficiency delivery of siRNA to hES cells. HUES9 cells were transfected with siRNA using StemAb RNA Transfection Kit. (A) Greater than 90% of hES cells were transfected with FAM labeled control siRNA, 75 nM (250 ng).

153683991400-0069_figure3c

High efficiency delivery of siRNA to hES cells. HUES9 cells were transfected with siRNA using StemAb RNA Transfection Kit. (C) Transfection with 10nM and 20nM Oct4 siRNA results in altered colony morphology.

153683986300-0069_figure3b

High efficiency delivery of siRNA to hES cells. HUES9 cells were transfected with siRNA using StemAb RNA Transfection Kit. (B) Transfection with Oct4 siRNA, 20 nM (250 ng), resulted in altered colony morphology and expression of SSEA-1 indicating differentiation.

153683988400-0069_figure4a

Human embryonic stem (hES) cells remain undifferentiated after transfection. H1 hES cells cultured in NutriStem were transfected with eGFP mRNA using StemAb RNA Transfection Kit. (A) Greater than 95% of cells maintained pluripotency marker expression, SSEA-4, 24 hours post-transfection.

153683994700-0069_figure4b

Human embryonic stem (hES) cells remain undifferentiated after transfection. H1 hES cells cultured in NutriStem were transfected with eGFP mRNA using StemAb RNA Transfection Kit. (B) Normal colony morphology is maintained 20 hours post-transfection.

 

Specifications

Product Name: StemFect RNA Transfection Kit

Catalog Number: 00-0069

Size: 1 Kit

Set Contents:

  • RNA Transfection Reagent: 750 µL
  • RNA Transfection Buffer: 30 mL

Storage and Stability: RNA Transfection Reagent should be stored at 4 °C and is stable for 6 months when stored as directed. RNA Transfection Reagent is dissolved in ethanol; the vial should be capped immediately after use to minimize evaporation. RNA Transfection Buffer may be stored at −20 °C or 4 °C and is stable for 6 months when stored as directed.

Quality Control: RNA Transfection Reagent has been characterized by mass spectrometry and NMR. StemAb RNA Transfection Kit is functionally tested for transfection efficiency on human fibroblast cells using eGFP mRNA.

Notice To Purchaser: This product is intended for research purposes only. It may not be used for (i.) any human or veterinary use, including without limitation therapeutic and prophylactic use, including without limitation drug delivery and nucleic acid delivery, (ii.) any clinical use, including without limitation diagnostic and prognostic use, (iii.) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, drug development, (iv.) any use in delivery of mRNA, saRNA, siRNA, ssRNA, miRNA and/or combinations thereof for the manufacture of recombinant therapeutic proteins, therapeutic antibodies and vaccines, (v.) any use in delivery to and/or modification of cells that are intended for clinical, diagnostic or medicinal use, including without limitation, cell-based therapy, or (vi.) any commercial purposes, including without limitation the performance of contract research or provision of services to a third party and the manufacture of products for general sale. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.

Documents

Protocols

Product Sheets

References

  1. Magadum A; Ding Y; He L; Kim T; Vasudevarao MD; Long Q; Yang K Wickramasinghe N; Renikunta HV; Dubois N; Veidinger G; Yang Q; Engel FB. Live cell screening platform identifies PPARgamma as a regulator of cardiomyocyte proliferation and cardiac repair. Cell Res 27:1002 (2017).
  2. Mohammed FH; Khajah MA; Yang M; Brackenbury WJ; Luqmany YA. Blockade of voltage-gated sodium channels inhibits invasion of endocrine-resistant beast cancer cells. Int J Oncology 48.1:73 (2016).
  3. Hansson ML; Albert S; Somermeyer LG; Peco R; Mejia-Ramirez E; Montserrat N; Belmonte JCI. Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigment epithelial cells. J Biol Chem 290:5661 (2015).
  4. Yen B; Mulder LCF; Martinez S; Basler CF. Molecular Basis for Ebolavirus VP34 Supression of Human Dendritic Cell Maturation. J Virol 88:12500 (2014).
  5. Chen Y; Zhang L; Estaras C; Choi SH; Moreno L; Karn J; Moresce JJ; Yates JR; Jones KA. A gene-sepcific role for the Ssu72 RNAPII CTD phosphatase in HIV-1 Tat transactivation. Genes and Dev 28:2261 (2014).
  6. Phua KKL; Leong KW; NairSK. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. Journal of Controlled Release 166: 227(2013).

Additional Publications